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Abstract: Mutations in isocitrate dehydrogenase (IDH) or a reduced expression of
L-2-hydroxyglutarate (HG)-dehydrogenase result in accumulation of D-2-HG or L-2-HG, respectively,
in tumor tissues. D-2-HG and L-2-HG have been shown to affect T-cell differentiation and activation;
however, effects on human myeloid cells have not been investigated so far. In this study we analyzed
the impact of D-2-HG and L-2-HG on activation and maturation of human monocyte-derived
dendritic cells (DCs). 2-HG was taken up by DCs and had no impact on cell viability but diminished
CD83 expression after Lipopolysaccharides (LPS) stimulation. Furthermore, D-2-HG and L-2-HG
significantly reduced IL-12 secretion but had no impact on other cytokines such as IL-6, IL-10 or TNF.
Gene expression analyses of the IL-12 subunits p35/IL-12A and p40/IL-12B in DCs revealed decreased
expression of both subunits. Signaling pathways involved in LPS-induced cytokine expression (NFkB,
Akt, p38) were not altered by D-2-HG. However, 2-HG reprogrammed LPS-induced metabolic
changes in DCs and increased oxygen consumption. Addition of the ATP synthase inhibitor
oligomycin to DC cultures increased IL-12 secretion and was able to partially revert the effect of 2-HG.
Our data show that both enantiomers of 2-HG can limit activation of DCs in the tumor environment.
Keywords: isocitrate dehydrogenase; hydroxyglutarate; dendritic cells; tumor environment;
activation
1. Introduction
Point mutations in IDH1 and IDH2 are detected in different types of malignancies such as
glioma and glioblastoma [1–3], acute myeloid leukemia (AML), and head and neck squamous cell
carcinoma (HNSCC). Data from glioma patients show a positive correlation between mutated IDH and
overall survival [4], whereas the prognostic impact of IDH mutations in AML varies across studies [5].
All mutations are generally heterozygous and it has been shown that mutated IDH gains the ability to
convert αKG into the oncometabolite D-2-HG.
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Moreover, increased levels of 2-HG in tumor tissues have been described in tumor entities lacking
IDH mutations. In breast cancer [6], 2-HG accumulation is based on increased glutamine uptake and
glutaminolysis. In renal cell carcinoma [7], the L-enantiomer of 2-HG (L-2-HG) accumulates based on
reduced expression of L-2-HG dehydrogenase, the enzyme which normally degrades L-2-HG. In both
cancer entities, 2-HG accumulation is associated with worse prognosis.
T-cells and DCs play a pivotal role in anti-tumor immune response. Accordingly, good prognosis
in cancer patients is associated with high T-cell density [8]. T-cell infiltration has also been shown to
have a positive impact on survival probability in patients with malignant gliomas [9,10]. Furthermore,
T-cell associated genes are enriched in high-grade astrocytoma in long-term compared with short-term
survivors [11]. Interestingly, in renal cell carcinoma as well as in head and neck cancers, T-cell
infiltration seems to be controlled by the metabolic phenotype of the tumor, as an accelerated tumor
glucose metabolism has been associated with a low CD8 effector T-cell infiltration [12].
Several studies suggest an interplay between tumor metabolism and immune cell metabolism [13].
The accelerated glucose and amino acid uptake of cancer cells may limit nutrient availability for
tumor-infiltrating immune cells. Furthermore, metabolic waste products, such as lactate or 2-HG, have
been shown to alter immune cell function. Human monocyte activation and DC differentiation is
compromised by lactic acid [14,15] and T- and NK-cell function is impaired in lactate-rich tumors [16].
Recently, Bottcher et al. reported that D-2-HG is taken up by T-cells and is enriched in T-cells in
patients with AML blasts that harbor mutant IDH [17]. They showed that exogenous D-2-HG shifts the
metabolism of activated human T-cells from aerobic glycolysis towards respiration, thereby favoring
the differentiation of regulatory T cells but diminishing Th17 polarization [18]. In line, IDH mutations
are associated with low CD8+ T-cell abundance in gliomas, indicating an impact of 2-HG on T-cells not
only in vitro but also in tumor patients [19,20]. In line, Bunse et al. recently described that inhibition
of the enzymatic function of mutant IDH1 improves antitumor immunity in IDH1-mutant tumors [21].
Moreover, IDH mutant gliomas downregulate the NKG2D gene via epigenetic silencing, which in
turn reduces NK-cell activation [22]. These data demonstrate a possible involvement of 2-HG in the
immune evasion of tumors.
The influence of D-2-HG on human myeloid cells, especially DCs, has not been investigated so
far. DCs are specialized antigen presenting cells that acquire, process, and present tumor-associated
antigens to T-cells for the induction of a tumor-specific immune response [23]. Mature and functional
active DCs seem to be absent in many tumor entities, resulting in a failure to generate a tumor-specific
T-cell response; possible underlying mechanisms include the accumulation of immunosuppressive
factors. Cytokines such as IL-10, TGF-β, and vascular endothelial growth factors are known to reduce
DC development and function in the tumor environment [24,25]. DC activation depends on the switch
from a mitochondrial to a glycolytic metabolism which supports the migratory ability of DCs [26].
Based on the obvious importance of DCs in the anti-tumor immune response, we investigated the
effect of D-2-HG and L-2-HG on activation and maturation of human DCs in vitro. Our data underline
the role of D-2-HG as an important, immunosuppressive metabolite in the tumor environment.
2. Results
2.1. Uptake of D-2-HG by DCs Has No Impact on DC Viability and Maturation
It has been shown that human T-cells take up 2-HG, which is accompanied by reprogramming
of T-cell metabolism and function. Here we measured cellular uptake of D-2-HG and L-2-HG by
monocyte-derived human DCs. Immature DC were stimulated with 100 ng/mL Lipopolysaccharides
(LPS) and treated with 10 mM D-2-HG or L-2-HG for 1 h or 24 h, respectively. Viability was measured
using the CASY system and revealed no impact of D-2-HG or L-2-HG on the viability of DCs (Figure 1a).
Intracellular levels of D-2-HG were analyzed by mass spectrometry and detected endogenous 2-HG in
DCs without 2-HG supplementation. Under treatment with 10 mM D-2-HG or L-2-HG, intracellular
levels of 2-HG in DCs increased about 100-fold (Figure 1b). This result demonstrates the capacity
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of DCs to take up 2-HG. Next, we analyzed the impact of D-2-HG on the maturation of DCs and
determined the expression of typical maturation markers after 24 h incubation with LPS by flow
cytometry. 2-HG neither changed classical DC marker expression such as CD1a nor co-stimulatory
molecule expression such as CD80 or CD86. However, the upregulation of CD83 was significantly
decreased (Figure 1c,d). Similar results were obtained using the L-enantiomer. In the absence of LPS,
both enantiomers did not alter surface marker expression (Figure 1e).
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Figure 1. Uptake of 2-hydroxyglutarate (HG) by dendritic cells (DCs) has no impact on DC viability
and maturation. (a) Human DCs were differentiated from elutration-separated monocytes in the
presence of FCS, GM-CSF, and IL-4. On day seven, immature DCs were stimulated with 100 ng/mL
LPS in the presence or absence of 10 mM 2-HG for 24 h and viability was analyzed using the CASY cell
analyzer system. Data repres nt the edian o 10 independent experiments with DCs from different
donors. (b) Uptak of -2-HG and L-2-HG by DC was analyzed after stimulation with 100 ng/mL
LPS in the presence or absence of 10 mM 2-HG for 1 h or 24 h. Cells were washed ith PBS and
intracellular levels of 2-HG were analyzed by mass spectrometry. Statistical analysis was performed
with the Wilcoxon-Test (** p ≤ 0.01). (c,d) The expression of typical DC markers on DCs stimulated for
24 h with 100 ng/mL LPS in the absence or presence of 2-HG was analyzed by flow cytometry. (e) As a
control, DCs were cultured in the absence or presence of 2-HG without LPS stimulation.
2.2. D-2-HG Reduces IL-12 Secretion and mRNA Expression in DCs
Beside expression of costimulatory molecules, secretion of IL-12 by DCs is an important signal
for the induction of T-cell differentiation. Hence, we analyzed the capacity for IL-12 production by
DCs after treatment with D-2-HG and its enantiomer L-2-HG. Supernatants of DCs were collected and
cytokine production was determined by ELISA (Figure 2). D-2-HG as well as L-2-HG significantly
reduced IL-12 p70 secretion in a dose-dependent manner, indicating that not only D-2-HG but also
its physiological enantiomer has suppressive activity (Figure 2a,b). Based on these results, we were
int rested in h ther the production of other cytokines such as IL-10, IL-6, or TNF is als affected by
D-2-HG or L-2-HG. D 2-HG as well as L 2-HG slightly upregu ated IL-10 secretion, wh reas IL-6 and
TNF secretion were downregulated by trend (Figure 2c–e). As IL-12 is important for T-cell stimulation,
we next determined the capacity of DCs to stimulate T-cells in a mixed lymphocyte reaction. Neither
D-2-HG nor L-2-HG had an impact on T-cell proliferation (Figure 2f).
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Figure 2. 2-HG modulates LPS-stimulated cytokine secretion by DCs. Monocyte-derived DCs were
plated in 6-well plates. DCs were activated with 100 ng/mL LPS and in parallel exposed to D-2-HG
or L-2-HG for 24 h. Supernatants were collected and measured for IL-12 (a,b), IL-10 (c), IL-6 (d), and
TNF (e). The measurements were performed by commercially available ELISA’s. Data represent the
median f four independent experiments. Statistical analysis was tested using D nnet’s multiple
comparison test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). (f) Antigen present tion was analyz in a mixed
lymphocyte reaction. DCs were cultured in flasks in the absence or presence of LPS and 2-HG for 24 h,
r ested, d ltured it ll eic cell for another five days. Proliferation was determined
by [3H]-thymidine incorporation.
To confirm the reduction of IL-12 p70 secretion, we analyzed intracellular levels of the IL-12
subunits p35 and p40 by flow cytometry. For this purpose, DCs were stimulated with LPS in the
presence or absence of D-2-HG or L-2-HG and a protein transport inhibitor preventing the release of
IL-12. The percentage of double IL12 p35 and p40 positive cells were reduced in LPS plus D-2-HG
treated DCs compared to LPS-stimulated control DCs (Figure 3a).
Next, we analyzed gene expression levels of the IL-12 subunits p35 (IL-12A) and p40 (IL-12B).
LPS-stimulated DCs were treated with D-2-HG or L-2-HG for 4 or 24 h and gene expression was
determined by RT-qPCR analysis. After stimulation with 100 ng/mL LPS, we detected a strong
expression of IL-12A and IL-12B genes. Treatment with D-2-HG or L-2-HG significantly decreased
expression after 4 h (Figure 3b,c); after 24 h the effect was no longer significant for IL-12A but was still
significant for the expression of IL-12B (Figure 3d,e).
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Figure 3. D-2-HG reduces intracellular IL-12 levels and mRNA expression in DCs.
(a) Monocyte-derived immature dendritic cells (iDCs) were activated with 100 ng/mL LPS with
or without D-2-HG in the presence of monensin. Intracellular levels of IL-12 p35 and IL-12 p40
were analyzed by flow cytometry. One representative experiment out of three is shown. (b,c)
Monocyte-derived iDCs were activated with 100 ng/mL LPS with or without D-2-HG or L-2-HG
for 4 h (b,c) or 24 h (d,e). RNA was isolated from cell lysates. After reverse transcription, the samples
were analyzed by RT-qPCR. Gene expression of IL-12p70 subunits IL-12A and IL-12B relative to 18S
RNA are shown. Data represent the median of three independent experiments. Statistical analysis was
tested using an Ordinary One-Way Test with Dunnet’s multiple comparison test (* p ≤ 0.05, ** p ≤ 0.01,
*** p ≤ 0.001).
2.3. D-2-HG and L-2-HG Have No Impact on LPS-Associated Signal ng Pathways in DCs
As we detected a strong impact of 2-HG on IL-12 secretion and gene expression, we investigated
signaling pathways associated with LPS-induced cytokine production. As exposure of DCs to LPS is
Int. J. Mol. Sci. 2019, 20, 742 6 of 14
known to activate nuclear factor (NF)-kB, Akt, and p38 pathways [27] we stimulated DCs with LPS and
2-HG and analyzed the expression of IkBα, P-Akt, and P-p38 by western blot. Proteasomal degradation
of IkBα is a key step in the regulation of the NFκB pathway and leads to nuclear translocation and
activation of gene expression. As expected, LPS reduced IkBα expression. However, 2-HG treatment
showed no significant effect on IκBα expression (Figure 4a).
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Figure 4. 2-HG has no impact on LPS-associated signaling. DCs were stimulated with LPS (100 ng/mL)
and treated with or without 10 mM 2-HG. After 1 h (IκB) or 24 h (P-Akt, P-p38) of treatment, cell
pellets were lysed and analyzed by western blot. (a) IκB expression was analyzed in DCs treated with
LPS alone or in combination with 2-HG. Data represent the median of six independent experiments.
Statistical analysis was tested with the Kruskal-Wallis Test (* p ≤ 0.01, *** p ≤ 0.001). (b,c) P-Akt and
P-p38 protein expression in DCs treated with LPS alone or in combination with 2-HG were analyzed.
Data represent the median of four independent experiments. Statistical analysis was performed using
the Kruskal-Wallis test.
Akt is a serine/threonine-specific protein kinase and is known to directly regulate IL-12
production [28]. LPS increased the amount of P-Akt and reduced the Akt content at the same time,
although statistical significance was not reached. D-2-HG and L-2-HG had no impact on these
alterations (Figure 4b). Next, we analyzed the effect of D-2-HG and L-2-HG on the p38 signaling
pathway. LPS stimulation had no significant impact on the expression of P-p38, and addition of 2-HG
did not change P-p38 levels (Figure 4c). These results suggest that suppression of IL-12 production is
not related to an impairment of the LPS-associated NF-kB, Akt, and p38 signaling pathways, although
other pathways might be involved.
2.4. 2-HG Reprograms DC Metabolism—Impact of Mitochondrial Activity on IL-12 Secretion
It has been shown that stimulation and maturation of murine and human DCs with LPS stimulates
glycolysis and decreases respiration [29,30]. In orde o evaluate th effect of 2-HG on glycolysis
and respiration we measured lactate l vels in cell culture superna ants nd utilized high-resoluti
respirometry to determine respiration. LPS increased lactate secretion which was partially suppressed
by the addition of 2-HG (Figure 5a). In addition, LPS stimulation significantly decreased oxygen
consumption of DCs. This effect was reduced in the presence of 2-HG (Figure 5b,c).
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secretion was determined in supernatants of DCs incubated in the presence or absence of 2-HG.
(b,c) Monocyte-derived DCs were placed in oxygraph chambers in culture medium. After stabilization
of respiration, 2-HG or medium was added to the chambers. After 10 min, cells were activated
with 100 ng/mL LPS and oxygen consumption was monitored for one hour. (b) One representative
experiment out of eight is shown. (c) Data represent the median of 11 independent experiments.
Statistical testing was performed using a RM One-Way ANOVA test with Holm Sidak’s multiple
comparison test (* p ≤ 0.05). (d) To evaluate the effect of oligomycin on IL-12 production by DCs,
.2 × 106 monocyte-derived DCs were plated in 24-well plates and treated with 10 ng/mL LPS and the
indicat d conc ntrations of oligomycin. IL-12 was measured in supernatants by commercially available
ELISA. Data represent the median of at least four independent experiments. Statistical significanc was
tested usi g the Kru kal Wallis test. (* p ≤ 0.05). (e) Monocyte-derived DCs were pla in 24-well
plates and treat d with 100 ng/mL LPS and with 2-HG in combin ion with oligomycin. IL-12 was
measured in supernatants by commercially available ELISA. Data represe t the median of at least four
ind pendent experiments. Statistical significance was tested using the Kruskal Wallis tes . (* p ≤ 0.05,
** p ≤ 0.01, *** p ≤ 0.001).
Oxygen consumption related to ATP production was also significantly reduced after LPS addition
and this effect was preve ted by the addition f D-2-HG. Furthermore, the capacity of the electron
transfer system was higher in D-2-HG treated cells (data not shown). These data point towards
reduced sub trate flux into mitochondria upon s imulation with LPS, which was counteracted by
D-2-HG. These results suggest that LPS stimulation shifts the metabolism of DCs from Oxidative
phosphorylation (OXPHOS) to ae obic glycolysis. D-2-HG prevents these metabolic alterations, which
might contribute t a reduced IL-12 secretion. To analyze whether the reductio in mitochondrial
respiration is directly linked to IL-12 production, we inhibited mitocho drial activi y by oligomycin and
easured IL-12 secretion in DC super atan s. i as positively affected by treatment
with low concentrations (0.05 µM) of oligomycin (Figure 5d). A combination of D-2-HG and L-2-HG
with low concentrations of ligomycin partially rescued IL-12 secretion (Figure 5e).
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3. Discussion
In different tumor entities 2-HG accumulation is associated with worse prognosis and recent
data suggest a negative correlation between 2-HG levels in gliomas and the anti-tumor immune
response [21,31]. The impact of D-2-HG on T-cells has been documented recently [17,21] but no data
are available regarding the effects of 2-HG on human DCs. Up to now, most studies have concentrated
on the effects of D-2-HG as IDH mutations are associated with elevated levels of the D-enantiomer.
However, in kidney tumors elevations of the L-enantiomer have been described [7]. Here, accumulation
of L-2-HG is mediated by a reduced expression of L-2-HG-dehydrogenase, which metabolizes L-2-HG
back to ketoglutarate. Therefore, not only D-2-HG but also L-2-HG may act as an oncometabolite.
Interestingly, Tyrakis et al. have described the suppression of IFNα production, decreased cytotoxicity,
and reduced viability after treatment of murine T-cells with 0.5 mM L-2-HG, which represents a very
low concentration compared to 20 mM 2-HG levels described in glioma [21,32]. In our experiments,
L-2-HG and D-2-HG had comparable effects on DCs, indicating that not only D-2-HG but also L-2-HG
is a potent modulator of the immune response.
IL-12 p70 secretion by DCs was significantly decreased in LPS-stimulated DCs in the presence of
physiological amounts of D-2-HG or L-2-HG (10 mM). In contrast, secretion of other cytokines was not
significantly changed. In line, the transcription of IL-12A and IL-12B was decreased. As IL-12 is not
only a marker for DC activation but also a marker for successful maturation, we analyzed the impacts
of D-2-HG and L-2-HG on DC maturation. After seven days of differentiation with GM-CSF and IL-4,
immature DCs were incubated for another 24 h with LPS. With the exception of CD83 expression,
no changes in surface marker expression were detected, indicating a very specific effect of 2-HG on
DC maturation.
Based on these data, we investigated the impact of 2-HG on pathways involved in LPS signal
transduction. Upon LPS stimulation, DCs activate NFκB, Akt, and p38 pathways [27]. Activation
of the PI3K/Akt pathway has been shown to inhibit IL-12 secretion in human monocytes [28] and
in murine DCs [33]; however, the opposite effect has been described for human monocyte-derived
macrophages and DCs [34]. Mitogen-activated p38 protein kinases are also involved in the regulation
of LPS-stimulated IL-12 gene expression in macrophages [35]. In our experiments, all studied pathways
were not significantly changed by 2-HG treatment. Therefore, these pathways cannot be responsible
for the negative impact on IL-12 production.
It is well-known that metabolism is important for the activation, differentiation, and function
of different types of immune cells. DCs increase glucose metabolism and decrease OXPHOS after
LPS stimulation [26]. Therefore, we wondered whether inhibition of IL-12 secretion by 2-HG could
be associated with an altered metabolism. A metabolic shift from OXPHOS towards glycolysis is
regarded as an important event in the activation process of LPS-stimulated macrophages [36] and
monocytes [14]. Furthermore, DC maturation has been linked to a reduction in OXPHOS and an
increase in glycolysis [30]. In our experiments, LPS treatment changed the metabolic profile of DCs in
a similar manner: LPS diminished OXPHOS in DCs, whereas lactate secretion was increased. 2-HG
treatment supported mitochondrial activity and slightly diminished glycolysis. In line, we could show
that 2-HG triggers an increase in OXPHOS and reduces the glycolytic activity of primary human
T-cells [17]. IDH1-mutated human oligodendroglioma cells with endogenous 2-HG production also
displayed increased OXPHOS activity in a xenograft mouse model [37]. Similar results have been
obtained by Grassian et al. [38] showing that tumor cells expressing mutant IDH1 are more sensitive
to pharmacologic inhibition of oxidative metabolism compared to IDH1 wildtype cells. Other studies
have shown contradictory effects of 2-HG on respiration in tumor cells. Chan and colleagues have
observed that D-2-HG inhibits mitochondrial cytochrome c oxidase (COX) activity in AML cells [39].
Fu et al. have reported an inhibition of respiration and ATP synthase in glioblastoma cells by D-2-HG
and L-2-HG [40]. These data indicate that primary cells and tumor cells may differ in their metabolic
response to 2-HG. Furthermore, exogenous application of 2-HG versus endogenous production in IDH
mutated cells may explain the different effects on cell metabolism.
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Malinarich has stated that tolerogenic DCs are characterized by increased OXPHOS, reduced
glycolysis, and low IL-12 production [30]. This phenotype resembles DCs treated with 2-HG, and
could indicate that 2-HG induces tolerogenic DCs. However, as costimulatory molecules such as CD80
and CD86 as well as MHC II molecules were not altered by 2-HG treatment, it seems unlikely that
HG-treated DCs cannot induce T-cell proliferation. In line, we did not find an impact of 2-HG on
antigen presentation as T-cell proliferation was not impaired. However, these data do not exclude the
possibility that HG-treated DCs may alter IFN-γ secretion by T-cells. It thus appears that different
aspects of LPS-induced DC maturation are regulated by different pathways and 2-HG targets mainly
metabolic changes and therefor IL-12 production. Further studies should clarify the impact of 2-HG
treatment on antigen presentation by DCs.
Interestingly, blocking mitochondrial respiration leads to an increase of IL-12 levels in the presence
of 2-HG. As drugs targeting respiration, such as metformin, are already being tested in tumor patients,
it may be possible to block OXPHOS in patients with IDH mutations or reduced L-2-HG-dehydrogenase
activity to relieve immunosuppression.
In conclusion, our results indicate that both the oncometabolite D-2-HG but also its enantiomer
L-2-HG impairs DC function by downregulation of IL-12 secretion, which potentially may contribute
to the immune escape of tumor cells in a tumor environment with 2-HG accumulation.
4. Materials and Methods
4.1. Cell Isolation and Culture
Peripheral blood mononuclear cells (PBMCs) of healthy donors were isolated by leukapheresis.
Leukapheresis was approved by the Ethics committee of the University Hospital Regensburg (Ethic
Vote July 2010 #09/066b and #09/066c); all human participants gave written informed consent.
Human monocytes were isolated from PBMCs by density gradient centrifugation over Ficoll/Hypaque
followed by counterflow centrifugation elutriation [41]. Immature dendritic cells (iDC) were generated
from human blood monoctes. Monocytes were cultured in culture flasks at a concentration of
1 × 106 cells/1.5 mL in RPMI 1640 (Gibco, Waltham, MA, USA) for seven days. The medium was
supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine (Biochrom, Berlin, Germany),
50 U/mL penicillin (Gibco, Waltham, MA, USA), 50 U/mL of streptomycin (Gibco), 225 U/mL
granulocyte macrophage colony stimulating factor (GMCSF, Peprotech, Hamburg, Germany), and
144 U/mL recombinant IL-4 (Peprotech). Cell number, cell size, and cell viability were determined
using the CASY cell analyzer system (Casy® Modell TT, OLS Omni Life Science, Bremen, Germany).
Appropriate cursor settings for determining cell number and viability were established for each
cell type.
4.2. Mixed Lymphocyte Reaction (MLR)
Immature dendritic cells were generated from human blood monocytes. Monocytes were cultured
in culture flasks at a concentration of 1 × 106 cells/1.5 mL in RPMI 1640 for five days with 10% fetal
calf serum (FCS), 225 U/mL granulocyte macrophage colony stimulating factor (GMCSF, Peprotech)
and 144 U/mL recombinant IL-4 (Peprotech). LPS (Enzo, Life Sciences, Farmingdale, NY, USA) and
D-2-HG or L-2-HG (both Sigma-Aldrich, St. Louise, MO, USA) were added to iDC on day five in the
culture flasks. For MLR, different amounts of monocyte-derived DC were harvested on day seven.
DCs were washed and cocultured with allogeneic human T lymphocytes in RPMI containing 5% AB
serum, L-glutamine (2 mmol/L), penicillin (50 U/mL), and streptomycin (50 mg/mL). On day five of
coculture, 0.5 µCi/0.2 mL [3H]-thymidine (Hartmann Analytic, Braunschweig, Germany) was added,
and incorporated radioactivity was quantified after 24 h by means of a beta counter (Perkin Elmer,
Gaithersburg, Waltham, MA, USA). All samples were analyzed in triplicate.
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4.3. ELISA
For the determination of extracellular cytokine concentrations, supernatants were harvested and
cytokines were determined by means of commercially available ELISA kits (Duoset ELISA, R&D
Systems, Minneapolis, MN, USA).
4.4. Flow Cytometry
To analyze DC surface markers, monocytes were cultured in RPMI medium supplemented
with IL-4 and GM-CSF for seven days. DCs were treated with 100 ng/mL LPS for 24 h in the
absence or presence of 10 mM D-2-HG or L-2-HG. Cells were harvested and stained with anti-CD1a
& anti-HLA-DR (Beckman Coulter, Krefeld, Germany), anti-CD80 (Biolegend, San Diego, CA, USA),
anti-CD83 (eBioscience, San Diego, CA, USA), and anti-CD86 (BD Bioscience, Franklin Lakes, NY,
USA) at 4 ◦C for 30 min. After washing, DCs were resuspended in FACS wash buffer. Flow cytometric
measurement was performed using a BD FACS Calibur instrument (BD Bioscience).
For intracellular detection of IL-12 p35 and IL-12 p40, monocytes were cultured in RPMI medium
supplemented with IL-4 and GM-CSF. After seven days of culture, cells were treated with 100 ng/mL
LPS with or without 10 mM D-2-HG in the presence of a protein transport inhibitor containing
Monensin (BD GolgiStopTM, BD Bioscience, Franklin Lakes, NY, USA) for 16 h. DCs were washed,
permeabilized, and fixed using the BD Cytofix/CytopermTM Kit (BD Biosciences), followed by staining
with anti-IL-12 p40 (R&D), anti-IL-12 p35 (R&D), and the respective isotype controls. Cells were
analyzed using a BD FACS Calibur instrument (BD Bioscience).
4.5. Determination of 2-HG Uptake by Liquid Chromatography-Mass Spectrometry
2.5 × 106 DCs/well were seeded in a 6-well plate in a final volume of 4 mL and stimulated
with 100 ng/mL LPS in the absence or presence of 10 mM D-2-HG or L-2-HG for 24 h. Cell pellets
were precipitated in 500 µL methanol (80%) supplemented with 10 µL of stable isotope-labeled
internal standard solution (2,3,3-d3-2HG, C/D/N Isotopes Inc., Pointe-Claire, QC, Canada; 100 µM
in water). The pellet was washed twice consecutively with 100 µL methanol (80%). Further sample
preparation and HPLC-MS/MS analysis was performed as described in Voelxen et al. [42]. Metabolite
concentrations were normalized to cell counts.
4.6. Quantitative Real-Time PCR (qPCR)
2.5 × 106 DCs/well were seeded in a 6-well plate in a final volume of 4 mL and stimulated
with 100 ng/mL LPS in the absence or presence of 10 mM D-2-HG or L-2-HG for 4 or 24 h.
Total RNA of monocytes or macrophages was obtained using the RNeasy Mini Kit (Quiagen, Hilden,
Germany). Complementary DNA (cDNA) was synthesized with a M-MLV Reverse Transcriptase
kit (Promega, Madison, WI, USA) and amplified by qPCR with the QuantiFastSYBR Green PCR
Kit (Quiagen) using the Mastercycler Ep Realplex (Eppendorf, Hamburg, Germany). Primer
sequences were purchased from Eurofins MWG Operon, Germany. All data were normalized to
18S cDNA RNA. PCR reaction was carried out in a 96-well plate format adapted to the Eppendorf
Realplex Mastercycler EpGradient S system. The amount of amplified DNA relative to reference
gene 18S rRNA was measured through the emission of light by SYBR green dye after each
extension step. A melting curve was monitored to determine the specificity of the amplification
product. Primer sequences—IL-12A: Sense: GAAGATGTACCAGGTGGAGTTCAAGAC, Antisense:
GCTCATCACTCTATCAATAGTCACTGCC; IL-12B: Sense: ACCAGCAGCTTCTTCATCAGGGAC,
Antisense: ACGCAGAATGTCAGGGAGAAGTAGGA.
4.7. Western Blot Analysis
2.5 × 106 DCs/well were seeded in a 6-well plate in a final volume of 4 mL and stimulated
with 100 ng/mL LPS in the absence or presence of 10 mM D-2-HG for 1 or 24 h. Phospho-proteins
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were extracted as described earlier [43] and separated on a denaturating 12% acrylamide gel. After
western blotting, membranes were stained with anti-ikB-β (Santa Cruz, Dallas, TX, USA), anti-Akt
(Cell Signaling Technology, Danvers, MA, USA), anti-P-Akt (Cell Signaling Technology), anti-p38 (Cell
Signaling Technology), anti-P-p38 (Cell Signaling Technology), or anti-β-actin (Sigma Aldrich), in dry
milk (5%), and detection was performed by chemiluminescence (ECL). Actin expression was used
as a loading control (Sigma Aldrich, St Louis, MO, USA). Densitometric analyses were performed
by means of the ChemiDoc MP Imaging System and Image LabTM software (Bio-Rad Laboratories,
Hercules, CA, USA).
4.8. High-Resolution Respirometry
Mitochondrial respiratory activity was determined by high-resolution respirometry using the
oxygraph O2-k (Oroboros Instruments, Innsbruck, Austria). DCs were resuspended in fresh culture
medium and respiration of 1 × 106 cells/mL was measured at 37 ◦C. Data acquisition and analysis
was performed with DatLab4 software (Oroboros, Innsbruck, Austria), including calculation of the
time derivative of oxygen concentration, signal deconvolution dependent on the response time of
the oxygen sensor, and correction for instrumental background oxygen flux [44]. Data points were
recorded at 1 s time intervals. Routine respiration was measured in the first 20 min, after which D-2-HG
or medium was added. When determining the effect of D-2-HG on DCs, LPS was added 10 min after
D-2-HG incubation. Respiration was measured for one hour, leak respiration was determined after
addition of oligomycin (2 µg/106 cells), capacity of complex I to IV (ETS) after a stepwise titration of
FCCP (final concentration of 3 µM, 1 µM by step), and residual oxygen consumption (ROX) not related
to the respiratory system was measured after addition of rotenone (0.5 µM) and myxothiazol (2.5 µM).
All respiratory parameters were corrected for ROX, and mitochondrial oxygen consumption related to
ATP production was calculated as the difference between ROUTINE and LEAK respiration.
4.9. Statistics
Statistics were calculated using Graphpad Prism, Version 6 (La Jolla, CA, USA). Comparisons
between groups were performed using the appropriate statistical methods depending on Gaussian
distributions and number of groups and variables.
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